B. Long

发表

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Aromatase and COX-2 expression in human breast cancers

M. A. Blankenstein, J. Nortier, M. Blankenstein, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

A. Brodie, A. Thiantanawat, B. Long, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

W. Yue, Jiping Wang, B. Long, 1998, Breast Cancer Research and Treatment.

Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.

B. Long, A. Brodie, D. Jelovac, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

P. Kirschmeier, Ming Liu, A. Basso, 2007, Anti-cancer drugs.

Human breast cancer cells contain an error-prone DNA replication apparatus.

R. Hickey, L. Malkas, J. Sekowski, 1998, Cancer research.

A unique form of proliferating cell nuclear antigen is present in malignant breast cells.

R. Hickey, L. Malkas, J. Sekowski, 1998, Cancer research.

Aromatase and its inhibitors

A. Brodie, B. Long, Q. Lu, 1999, The Journal of Steroid Biochemistry and Molecular Biology.

Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti-PD-1 administration

I. Wang, R. Cristescu, N. Solban, 2020, Molecular medicine reports.

Sonoporation‐Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression

N. Solban, Jun Xu, A. Templeton, 2021, Advanced Therapeutics.

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens

B. Long, A. Brodie, D. Jelovac, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

D. Grigoryev, B. Long, A. Brodie, 1999, Breast Cancer Research and Treatment.

Aromatase inhibition and inactivation.

B. Long, A. Brodie, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aromatase inhibitors and their antitumor effects in model systems.

B. Long, A. Brodie, Q. Lu, 1999, Endocrine-related cancer.

Immunotherapy Response in Mouse Syngeneic Tumor Models

Derek Y. Chiang, K. Kerr, H. Hirsch, 2021 .

STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors

J. Cumming, Sarah Javaid, A. Tse, 2021, Molecular Cancer Therapeutics.

Treatment Strategies Using Letrozole and Tamoxifen in a Xenograft Model for Breast Cancer

A. Brodie, B. Long, A. Brodie, 2003 .

Small Molecule Therapeutics Preclinical Evaluation of the WEE 1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013 .

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

W. Miller, D. Evans, A. Brodie, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity

D. Grigoryev, W. Yue, Syreeta L. Tilghman, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.

Andrew M Haidle, Matthew L. Maddess, J. Cumming, 2022, Journal of medicinal chemistry.

Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.

A. Brodie, A. Thiantanawat, B. Long, 2003, Cancer research.

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

W. R. Bishop, P. Kirschmeier, B. Long, 2009, International journal of cancer.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

W. R. Bishop, P. Kirschmeier, Ming Liu, 2008, Gynecologic oncology.

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

E. Petricoin, A. Maitra, K. Wennerberg, 2016, Cancer cell.

Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor

V. Njar, D. Grigoryev, B. Long, 2000, The Journal of Steroid Biochemistry and Molecular Biology.

Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-Hydroxylase-C17,20-lyase (P45017α) : Potential agents for the treatment of prostate cancer

Katsuya Kato, Dmitry N. Grigoryev, V. Njar, 1998 .

An orally available non-nucleotide STING agonist with antitumor activity

Andrew M Haidle, J. Cumming, I. Kariv, 2020, Science.

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.

M. Lynch, B. Long, H. W. van den Berg, 1992, British Journal of Cancer.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

D. Grigoryev, A. Brodie, B J Long, 2000, Cancer research.

Reduced levels of cathepsin D associated with tamoxifen resistance and estrogen independence in the ZR-75-1 human breast cancer cell line.

B. Long, H. W. van den Berg, 1996, Cancer letters.

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Gauri Sabnis, B. Long, Danijela Jelovac, 2005, Cancer research.

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

B. Long, A. Brodie, G. Sabnis, 2005, Cancer research.

Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER.

D. Rose, B J Long, B. Long, 1996, Cancer letters.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

J. Ragaz, N. Macpherson, A. Brodie, 2004, Journal of the National Cancer Institute.

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.

W. Yue, B. Long, J. Wang, 1998, Oncology.

Model systems: Mechanisms involved in the loss of sensitivity to letrozole

A. Brodie, B. Long, O. Goloubeva, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model

J. Ingle, B. Long, A. Brodie, 2004, Clinical Cancer Research.

Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Andrew M Haidle, Chunsheng Zhang, Yongxin Han, 2021, Oncoimmunology.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model

V. Njar, A. Brodie, B. Long, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Anti-tumour effects and pharmacokinetic profile of 17-(5′ -isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis

D. Grigoryev, A. Brodie, B. Long, 2000, British Journal of Cancer.

Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.

Q. Lu, A. Brodie, B. Long, 1999, Endocrinology.

Aromatase expression in the human breast

B. Long, A. Brodie, Q. Lu, 2004, Breast Cancer Research and Treatment.

Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

V. Njar, D. Grigoryev, A. Brodie, 1999, British Journal of Cancer.

Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.

E. Huarte, B. Long, Ashish Juvekar, 2021, Immunotherapy.

Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus 1

R. Hickey, L. Malkas, J. Sekowski, 2006 .

Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus1

Lauren, Jennifer, R. Hickey, 2006 .

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

P. Kirschmeier, B. Long, Y. Hsieh, 2009, International journal of cancer.

The effect of alternating letrozole and tamoxifen in comparison to sequential treatment with each drug alone or in combination

A. Thiantanawat, B. Long, A. Brodie, 2001 .

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.